GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Cyclically Adjusted PS Ratio
中文

Xencor (Xencor) Cyclically Adjusted PS Ratio

: 7.31 (As of Today)
View and export this data going back to 2013. Start your Free Trial

As of today (2024-04-24), Xencor's current share price is $18.34. Xencor's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $2.51. Xencor's Cyclically Adjusted PS Ratio for today is 7.31.

The historical rank and industry rank for Xencor's Cyclically Adjusted PS Ratio or its related term are showing as below:

XNCR' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.84   Med: 12.04   Max: 20.9
Current: 7.24

During the past years, Xencor's highest Cyclically Adjusted PS Ratio was 20.90. The lowest was 6.84. And the median was 12.04.

XNCR's Cyclically Adjusted PS Ratio is ranked worse than
58.57% of 502 companies
in the Biotechnology industry
Industry Median: 5.375 vs XNCR: 7.24

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xencor's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.734. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.51 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Xencor Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Xencor's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 20.86 11.82 8.45

Xencor Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.82 12.32 10.68 8.23 8.45

Competitive Comparison

For the Biotechnology subindustry, Xencor's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xencor Cyclically Adjusted PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, Xencor's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xencor's Cyclically Adjusted PS Ratio falls into.



Xencor Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Xencor's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=18.34/2.51
=7.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xencor's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Xencor's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.734/129.4194*129.4194
=0.734

Current CPI (Dec. 2023) = 129.4194.

Xencor Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.070 99.695 0.091
201406 0.026 100.560 0.033
201409 0.027 100.428 0.035
201412 0.180 99.070 0.235
201503 0.043 99.621 0.056
201506 0.025 100.684 0.032
201509 0.087 100.392 0.112
201512 0.537 99.792 0.696
201603 0.179 100.470 0.231
201606 1.581 101.688 2.012
201609 0.191 101.861 0.243
201612 0.635 101.863 0.807
201703 0.075 102.862 0.094
201706 0.267 103.349 0.334
201709 0.000 104.136 0.000
201712 0.642 104.011 0.799
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.498 106.507 0.605
201812 0.206 105.998 0.252
201903 1.930 107.251 2.329
201906 0.345 108.070 0.413
201909 0.384 108.329 0.459
201912 0.060 108.420 0.072
202003 0.569 108.902 0.676
202006 0.229 108.767 0.272
202009 0.618 109.815 0.728
202012 0.727 109.897 0.856
202103 0.586 111.754 0.679
202106 1.118 114.631 1.262
202109 0.337 115.734 0.377
202112 2.527 117.630 2.780
202203 1.400 121.301 1.494
202206 0.507 125.017 0.525
202209 0.457 125.227 0.472
202212 0.361 125.222 0.373
202303 0.317 127.348 0.322
202306 0.761 128.729 0.765
202309 0.976 129.860 0.973
202312 0.734 129.419 0.734

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xencor  (NAS:XNCR) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Xencor Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Xencor's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xencor (Xencor) Business Description

Industry
Traded in Other Exchanges
Address
111 West Lemon Avenue, Monrovia, CA, USA, 91016
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Executives
Bassil I Dahiyat director, officer: PRESIDENT & CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang officer: SR. VICE PRESIDENT & CMO C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Celia Eckert officer: VP, GENERAL COUNSEL C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais officer: SR. VICE PRESIDENT & CSO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John J Kuch officer: SR. VICE PRESIDENT & CFO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Richard J Ranieri director 3005 FIRST AVE, SEATTLE WA 98121
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Kevin Charles Gorman director 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kurt A Gustafson director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Stafford John S Iii 10 percent owner 230 SOUTH LASALLE STREET 400, CHICAGO IL 60604